INMNasdaqPharmaceutical PreparationsFiscal year ends June 30
InMed Pharmaceuticals Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 9, 2026
$1.37+0.05 (+3.44%)
Close on Oct 19, 2026
- Market cap
- $6.42M
- P/E (TTM)
- –
- Dividend yield
- –
InMed Pharmaceuticals Inc. revenue by segment
By business segment
| Operating income | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | YoY |
|---|---|---|---|---|---|---|
| BayMedica [Member] | – | – | – | -$1.21M | -$5.19M | – |
| InMed [Member] | – | – | – | -$6.74M | -$13.41M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of InMed Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.